Prediction Case File
YouTubeTracking Live

Solana Crashed 97%, Then Went 37x.. Again? #shorts

1 extracted signal · 0 resolved · 1 still active

Marzell Crypto profile imageMarzell CryptoIndependent analyst profile
Source published
11 Nov 2026, 11:18 UTC
Recorded by Tahlil Plus
11 Nov 2026, 15:23 UTC
Video preview for Solana Crashed 97%, Then Went 37x.. Again? #shorts
Source overview

AI-generated source summary

The video analyzes Solana's historical cycle patterns following significant crashes and projects a long-term bottom leading up to a new high by 2028. For immediate trade execution, a limit buy is set at 77.50 with a stop loss at 66.00 and a target price of 108.00 based on recent price action and support levels.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

Marzell Crypto

Platform-wide history, separate from this source evaluation.

Reliability
47.8
Tracked signals
7
Historical success
50.0%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail